On January 11, 2021 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, reported a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference (Press release, Deciphera Pharmaceuticals, JAN 11, 2021, View Source [SID1234573777]). The Company will webcast its presentation today at 9:10 AM ET at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Building on the successful U.S. launch of QINLOCK last year, we are focused in 2021 on expanding both the geographic reach for QINLOCK and the potential for this medicine to benefit patients with GIST even earlier in the course of their disease," said Steve Hoerter, President and Chief Executive Officer of Deciphera. "We also look forward to sharing updated data from the vimseltinib (DCC-3014) and rebastinib programs, as well as finalizing our development plans to support potential registration for these two product candidates. With continued execution and investment in our pipeline, we believe we are well positioned to realize our 2021 goals and deliver important new medicines to patients."

In 2021, the Company seeks to achieve the following milestones:

QINLOCK (ripretinib)

Report top-line data from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with second-line gastrointestinal stromal tumor (GIST) in the second half of 2021.
Receive approval from the European Medicines Agency (EMA) for QINLOCK for the treatment of patients with fourth-line GIST in the second half of 2021.
Vimseltinib (DCC- 3014)

Present updated data from the Phase 1/2 study of vimseltinib (DCC-3014), an inhibitor of CSF1R, in patients with tenosynovial giant cell tumor (TGCT) in the second half of 2021.
Finalize the pivotal development plan for vimseltinib in TGCT in the second half of 2021.
Rebastinib

Present updated data from its Phase 1b/2 study of rebastinib, an inhibitor of TIE2, in combination with paclitaxel for patients with endometrial cancer in the second quarter of 2021.
Present updated data from its Phase 1b/2 study of rebastinib in combination with paclitaxel for patients with platinum-resistant ovarian cancer in the second half of 2021.
Finalize the pivotal development plan for the rebastinib/paclitaxel combination in the second half of 2021.
DCC-3116

Initiate the Phase 1 study of DCC-3116, an inhibitor of ULK kinase for the potential treatment of patients with cancers driven by mutations in RAS genes, in the second quarter of 2021, subject to FDA authorization to proceed under the investigational new drug (IND) application submitted in the fourth quarter of 2020.
Presentation at 39th Annual J.P. Morgan Healthcare Conference
Deciphera will webcast its corporate presentation from the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at deciphera.com. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation. In conjunction with the conference, the Company has also updated its corporate presentation, which can be found here: View Source